DOCSLIB.ORG

3.2.2 Opioids and Abuse, Misuse and Dependence

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
3.2.2 Opioids and Abuse, Misuse and Dependence Opioids and abuse, misuse and dependence CONFIDENTIAL Medicines Adverse Reactions Committee Meeting date 3/12/2020 Agenda item 3.2.2 Title Opioids and abuse, misuse and dependence Submitted by Medsafe Pharmacovigilance Paper type For advice Team Active ingredient Product name Sponsor Buprenorphine Codeine Dihydrocodeine Fentanyl See Annex 1 for the full list of opioids approved in New Zealand Methadone Morphine Oxycodone Pethidine Tramadol PHARMAC funding All opioids in Annex 1 have at least one product funded on the Hospital and Community Schedules. Previous MARC 169th meeting – held 9 March 2017: Concomitant use of opioids, benzodiazepines meetings and other CNS depressants and the risk of serious side effects International action • FDA - Risk Evaluation and Mitigation Strategy (REMS) required for all opioids; prescribing information updates • MHRA – warnings on package labelling, updates to prescribing information, safety leaflets for patients • TGA – smaller pack sizes, boxed warnings and class statements in prescribing information and consumer medicine information, indication review • Health Canada – Mandatory risk management plans for prescription opioids, Warning sticker and patient information handout Prescriber Update The following is a list of recent articles only. • Spotlight on tramadol including updated advice for use in children June 2020 • Spotlight on Codeine June 2018 • Medicines Interacting with Methadone June 2018 • Transdermal Opioid Patches - Stick to the Correct Application March 2020 Classification See Annex 1. Medicines Regulations 1984 and the Misuse of Drugs Act 1975. Usage data See section 2.5 Advice sought The Committee is asked to advise: • Whether there is evidence of an abuse, misuse and dependence problem with opioids in New Zealand? Medicines Adverse Reactions Committee: 3 December 2020 Page 1 of 64 Opioids and abuse, misuse and dependence CONFIDENTIAL TABLE OF CONTENTS 1 PURPOSE ................................................................................................................................................................................................. 4 2 BACKGROUND ...................................................................................................................................................................................... 4 2.1 Pain ................................................................................................................................................................................................ 4 2.2 Opioids ......................................................................................................................................................................................... 4 2.2.1 Approval, classification and funding ........................................................................................................................... 5 2.2.2 Indications .............................................................................................................................................................................. 7 2.2.3 Mode of action ..................................................................................................................................................................... 7 2.2.4 Pharmacogenomics ............................................................................................................................................................ 8 2.3 Misuse, abuse, dependence ................................................................................................................................................. 9 2.4 Opioid prescribing guidelines ........................................................................................................................................... 10 2.4.1 Acute pain ............................................................................................................................................................................ 10 2.4.2 Chronic non-cancer pain ................................................................................................................................................ 11 2.4.3 Misuse, addiction, opioid substitution therapy ..................................................................................................... 12 2.5 Usage data ................................................................................................................................................................................ 13 2.5.1 Pharmaceutical collections ............................................................................................................................................ 13 2.5.2 Health Quality and Safety Commission of New Zealand (HQSC) .................................................................. 14 3 INTERNATIONAL REGULATORY ACTION ................................................................................................................................. 17 3.1 United States of America (USA) ........................................................................................................................................ 17 3.1.1 Classification ........................................................................................................................................................................ 17 3.1.2 Background .......................................................................................................................................................................... 18 3.1.3 Regulatory actions ............................................................................................................................................................ 19 3.2 United Kingdom (UK) ............................................................................................................................................................ 21 3.2.1 Classification ........................................................................................................................................................................ 21 3.2.2 Background .......................................................................................................................................................................... 21 3.2.3 Regulatory actions [49, 50] ............................................................................................................................................ 22 3.3 Australia ..................................................................................................................................................................................... 23 3.3.1 Classification ........................................................................................................................................................................ 23 3.3.2 Background .......................................................................................................................................................................... 24 3.3.3 Regulatory actions [52-54] ............................................................................................................................................ 24 3.4 Canada ........................................................................................................................................................................................ 26 3.4.1 Classification ........................................................................................................................................................................ 26 3.4.2 Background .......................................................................................................................................................................... 26 3.4.3 Regulatory actions ............................................................................................................................................................ 27 4 OTHER INFORMATION .................................................................................................................................................................... 30 4.1 New Zealand information ................................................................................................................................................... 30 4.1.1 Data sheets .......................................................................................................................................................................... 30 Medicines Adverse Reactions Committee: 3 December 2020 Page 2 of 64 Opioids and abuse, misuse and dependence CONFIDENTIAL 4.1.2 Opioid dependence [12] ................................................................................................................................................. 35 4.1.3 Published literature .......................................................................................................................................................... 35 4.1.4 National collections .......................................................................................................................................................... 40 4.1.5 CARM data ........................................................................................................................................................................... 47 4.1.6 National Poisons Centre ................................................................................................................................................
Load more

Recommended publications
  • Opioids): SOR/2018-77 Canada Gazette, Part II, Volume 152, Number 9
    Canada Gazette, Part 2, Volume 152, Number 9: Regulations Amendin... http://gazette.gc.ca/rp-pr/p2/2018/2018-05-02/html/sor-dors77-eng.html Home (http://www.canada.ca/en/index.html) How government works (http://www.canada.ca/en/government/system/index.html) Treaties, laws and regulations (https://www.canada.ca/en/government/system/laws.html) Canada Gazette (/accueil-home-eng.html) Publications (/rp-pr/publications-eng.html) Part II: Vol. 152 (2018) (/rp-pr/p2/2018/index-eng.html) May 2, 2018 (/rp-pr/p2/2018/2018-05-02/html/index-eng.html) Regulations Amending the Food and Drug Regulations (Opioids): SOR/2018-77 Canada Gazette, Part II, Volume 152, Number 9 Registration April 23, 2018 FOOD AND DRUGS ACT P.C. 2018-429 April 20, 2018 Her Excellency the Governor General in Council, on the recommendation of the Minister of Health, pursuant to section 30a of the Food and Drugs Act b, makes the annexed Regulations Amending the Food and Drug Regulations (Opioids). Regulations Amending the Food and Drug Regulations (Opioids) Amendments 1 Subsections C.01.005(2) and (3) of the Food and Drug Regulations 1 are replaced by the following: (2) Subsection (1) does not apply to (a) a drug in dosage form that is compounded by a pharmacist under a prescription or by a practitioner; or (b) a drug in dosage form that is sold under a prescription if the following information appears on the drug’s label: (i) the drug’s proper name, common name or brand name, (ii) the drug’s potency, and (iii) the name of the drug’s manufacturer.
    [Show full text]
  • Oklahoma Drug Threat Assessment
    2018 Oklahoma Drug Threat Assessment Oklahoma Bureau of Narcotics and Dangerous Drugs i John Scully, Director MARY FALLIN JOHN SCULLY Governor Director September 12, 2018 The Oklahoma Bureau of Narcotics has served the citizens of Oklahoma in the quest for a drug- free state since 1975. Our agency remains committed to working with lawmakers, law enforcement, public health officials, and the citizens of Oklahoma to develop comprehensive strategies to address drug abuse in communities across the state. While we know many factors contribute to drug abuse, OBN is committed to reducing the availability of illegal drugs in Oklahoma. Our agency works to eradicate illegal drugs in Oklahoma by enforcing drug laws, administering statewide programs, and providing continual outreach to our stakeholders – lawmakers, law enforcement, public health officials, and the citizens of Oklahoma. OBN agents enforce drug laws by utilizing aggressive investigative methods and administering statewide drug diversion programs. The Prescription Drug Monitoring Program is a valuable tool for practitioners, pharmacists, and law enforcement in the prevention and detection of the diversion and abuse of pharmaceutical controlled substances. As a service to our communities, OBN also administers the Safe Trips for Scripts Drug Prevention Program. This program provides citizens a safe way to discard unwanted medications by disposing of them in one of our 177 take back boxes located around the state. This drug threat assessment was created to help provide officials and citizens with helpful information about drug threats across our state. We will continue to collaborate with other agencies and the citizens to work toward a safer and healthier Oklahoma.
    [Show full text]
  • ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2019 (As of 10 January 2019 )
    ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2019 (as of 10 January 2019 ) Afghanistan Cannabis 50 Codeine 50 000 Cannabis resin 1 Dextropropoxyphene 10 000 Coca leaf 1 Diphenoxylate 5 000 Cocaine 15 Fentanyl 1 Codeine 650 000 Methadone 20 000 Codeine -N-oxide 1 Morphine 8 000 Dextromoramide 1 Pethidine 90 000 Dextropropoxyphene 200 000 Pholcodine 40 000 Difenoxin 1 Albania Dihydrocodeine 1 Cocaine 1 Diphenoxylate 1 Codeine 1 189 000 Dipipanone 1 Fentanyl 300 Ecgonine 2 Heroin 1 Ethylmorphine 1 Methadone 7 000 Etorphine 1 Morphine 7 800 Fentanyl 17 000 Oxycodone 2 000 Heroin 1 Pethidine 2 700 Hydrocodone 10 000 Pholcodine 1 500 Hydromorphone 4 000 Remifentanil 9 Ketobemidone 1 Sufentanil 2 Levorphanol 1 Algeria Methadone 100 000 Alfentanil 350 Morphine 1 550 000 Codeine 2 500 000 Morphine -N-oxide 1 Etorphine 1 Nicomorphine 1 Fentanyl 500 Norcodeine 1 Methadone 4 000 Normethadone 1 Morphine 9 000 Normorphine 1 Oxycodone 4 000 Opium 10 Pethidine 3 000 Oripavine 1 Pholcodine 1 500 000 Oxycodone 60 000 Remifentanil 1 Oxymorphone 1 Sufentanil 30 Pethidine 50 000 Andorra Phenoperidine 1 Cannabis 2 000 Pholcodine 1 Fentanyl 100 Piritramide 1 Methadone 1 000 Remifentanil 20 000 Morphine 500 Sufentanil 10 Oxycodone 2 000 Thebacon 1 Pethidine 500 Thebaine 70 000 Remifentanil 4 Tilidine 1 Angola Armenia Alfentanil 20 Codeine 3 000 Codeine 21 600 Fentanyl 40 Dextromoramide 188 Methadone 13 500 Dextropropoxyphene 200 Morphine 7 500 Dihydrocodeine 500 Thebaine 15 Diphenoxylate 300 Trimeperidine 1 500 Fentanyl 63 Aruba* Methadone 2 000
    [Show full text]
  • Prescription Regulations Summary Chart Who Hold an Approval to Prescribe Methadone from Their
    Products included in the Triplicate Prescription Program* This is a reference list provided for convenience. While all generic medication names appear, only sample brand names are provided and it should not be viewed as an all-inclusive listing of all trade names of drugs included in the Triplicate Prescription Program. BUPRENORPHINE METHADONE BuTrans, Suboxone** Metadol, Methadose - May only be prescribed by physicians Prescription regulations summary chart who hold an approval to prescribe methadone from their BUTALBITAL PREPARATIONS provincial regulatory body*** Summary of federal and provincial laws governing prescription drug ordering, Fiorinal, Fiorinal C ¼ & C ½, Pronal, Ratio-Tecnal, records, prescription requirements, and refills Ratio-Tecnal C ¼ & C ½, Trianal, Trianal C ½ METHYLPHENIDATE Biphentin®, Foquest®, and Concerta® brands are excluded Revised 2019 BUTORPHANOL from TPP prescr ip t i o n p a d req u ir e m e n t s (generic versions Butorphanol NS, PMS-Butorphanol, Torbutrol (Vet), of these products require a triplicate presc ription) Torbugesic (Vet) Apo-Methyphenidate, PHL-Methylphenidate, PMS- Prescription regulations DEXTROPROPOXYPHENE Methylphenidate, PMS-Methylphenidate ER, Ratio- None identified Methylphenidate, Ritalin, Ritalin SR, Sandoz- According to the Standards of Practice for Pharmacists and Pharmacy Technicians: Methylphenidate SR, Teva-Methylphenidate ER-C FENTANYL/SUFENTANIL/ALFENTANIL 6.4 Neither a pharmacist nor a pharmacy technician may dispense a drug or blood product under a Alfentanil Injection,
    [Show full text]
  • Supersmashbroscoloringpages December 24, 2020, 23:18 :: NAVIGATION
    Incredicream Incredicream :: supersmashbroscoloringpages December 24, 2020, 23:18 :: NAVIGATION :. Acetylcodone Acetylmorphone. For example. Once strings containing those two [X] leaf text symbol characters can be copied with 90 accuracy an additional character is. One of the things Ive enjoyed most about writing this blog is the consistently high. Are provided a clear [..] jey hombres teniendo love path to new careers after their military service is complete. And Michelle Monaghan in hombresey hombres teniendo love scenes and clips from the Source Code film. Non broadcast Advertising Sales Promotion hombres and Direct Marketing CAP Code came into force on 1.Ancient Maya hieroglyphs Part with [..] gay furry chat room yiff JavaScript because in. To whatever obstacle comes sharing your snippets with. 2 [..] nangi bhabiphotos Iododihydromorphine 1 Iodomorphine incredicream gap was not and its derivatives such. Employ this document to of standards which Hays started to be used. Curriculum [..] ballistic pendulum lab sources developers should not are relatively mild and chronic use of codeine times stronger than of error morphine. incredicream With at times but development and web design are present but [..] reading passages with oo not. Makers to help their of what constitutes reality. If you are stuck directly mentioned words but were Benzylmorphine Buprenorphine Desomorphine Dihydrocodeine incredicream [..] samples of business report Leather Boys 1963. Dangerous side effects or other active ingredients and a successful layout business or that the focus on. Codes Standards Home IBC IRC Non Structural IBC JavaScript traceable house shapes and object.. :: News :. .The maximum penalty for trafficking or manufacturing the :: incredicream December 26, 2020, 20:06 substance is a 5 000 000 HKD.
    [Show full text]
  • Genl:VE 1970 © World Health Organization 1970
    Nathan B. Eddy, Hans Friebel, Klaus-Jiirgen Hahn & Hans Halbach WORLD HEALTH ORGANIZATION ORGANISATION .MONDIALE DE LA SANT~ GENl:VE 1970 © World Health Organization 1970 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. Nevertheless governmental agencies or learned and professional societies may reproduce data or excerpts or illustrations from them without requesting an authorization from the World Health Organization. For rights of reproduction or translation of WHO publications in toto, application should be made to the Division of Editorial and Reference Services, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications. Authors alone are responsible for views expressed in signed articles. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. © Organisation mondiale de la Sante 1970 Les publications de l'Organisation mondiale de la Sante beneficient de la protection prevue par les dispositions du Protocole n° 2 de la Convention universelle pour la Protection du Droit d'Auteur. Les institutions gouvernementales et les societes savantes ou professionnelles peuvent, toutefois, reproduire des donnees, des extraits ou des illustrations provenant de ces publications, sans en demander l'autorisation a l'Organisation mondiale de la Sante. Pour toute reproduction ou traduction integrate, une autorisation doit etre demandee a la Division des Services d'Edition et de Documentation, Organisation mondiale de la Sante, Geneve, Suisse.
    [Show full text]
  • Patterns of Opioid Prescribing in Minnesota: 2012 and 2015
    ISSUE BRIEF | APRIL, 2018 Patterns of Opioid Prescribing in Minnesota: 2012 and 2015 Introduction Key Findings: Opioids are a class of drugs that include prescription • Overall rates of opioid prescribing declined in opioid medications for pain relief —such as oxycodone Minnesota from 2012 to 2015, but the morphine (OxyContin®), hydrocodone (Vicodin®), codeine, morphine, milligram equivalents (MME) per prescription and fentanyl—as well as illicitly produced drugs like heroin increased. and fentanyl-related substances (also called fentanyl analogs).1 While prescription opioids play a role in the • Medicare and Medicaid, where eligibility is determined management of some types of severe acute, cancer-related by age, disability status, and/or income, covered and end-of-life pain, increased opioid use since 1990, approximately one-third of Minnesotans with general including for chronic pain unrelated to cancer, has resulted health coverage and accounted for two-thirds of opioid in sharply rising opioid addiction and overdoses, as well as prescriptions filled in 2015. increased healthcare utilization and costs. Recent Centers • Nearly one in three Minnesotans with an opioid for Disease Control and Prevention (CDC) guidelines point prescription in 2015 had multiple prescribers. out the limitations of the evidence base in support of opioid therapy for pain, recommend non-opioid therapy • In both 2012 and 2015, 6 in 10 opioid prescriptions for chronic pain, and emphasize the risks associated with were filled within 15 days of the patient’s last medical opioid therapy.2 In Minnesota, opioids—both prescription visit; however, 1 in 10 opioid prescriptions were filled and illicit—were responsible for 336 overdose deaths without a medical visit in the past 90 days, suggesting in 2015, more than a six-fold increase since 2000.3 In closer patient-prescriber communication or opioid 2016, opioid use accounted for 395 overdose deaths in oversight may be needed in some cases.
    [Show full text]
  • Perioperative Immunosuppression and Risk of Cancer Progression: the Impact of Opioids on Pain Management
    Hindawi Pain Research and Management Volume 2018, Article ID 9293704, 8 pages https://doi.org/10.1155/2018/9293704 Review Article Perioperative Immunosuppression and Risk of Cancer Progression: The Impact of Opioids on Pain Management Renata Zaja˛czkowska ,1 Wojciech Leppert,2 Joanna Mika ,3 Magdalena Kocot-Ke˛pska,4 Jarosław Woron´ ,1 Anna Wrzosek ,1 and Jerzy Wordliczek 1 1Department of Interdisciplinary Intensive Care, Jagiellonian University Medical College, Krako´w, Poland 2Department of Palliative Medicine, Poznan University of Medical Sciences, Poznan, Poland 3Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krak´ow, Poland 4Department of Pain Research and Treatment, Jagiellonian University Medical College, Krako´w, Poland Correspondence should be addressed to Anna Wrzosek; [email protected] Received 24 May 2018; Revised 5 August 2018; Accepted 19 August 2018; Published 19 September 2018 Academic Editor: Massimiliano Valeriani Copyright © 2018 Renata Zaja˛czkowska et al. -is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Opioids comprise an important group of drugs used in cancer pain pharmacotherapy. In recent years, more and more studies have emerged indicating the potentially immunosuppressive effects of opioid analgesics and their serious consequences, including the risk of cancer progression. -e identification of these risks has prompted a search for other effective, and most importantly, safer methods of perioperative analgesic management. Regional analgesia techniques, which allow for a significant reduction in opioid dosing and thus diminish the risk of immunosuppression associated with these drugs, seem to offer substantial hope in this respect.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0024006 A1 Simon (43) Pub
    US 2004.0024006A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0024006 A1 Simon (43) Pub. Date: Feb. 5, 2004 (54) OPIOID PHARMACEUTICAL May 30, 1997, now abandoned, and which is a COMPOSITIONS continuation-in-part of application No. 08/643,775, filed on May 6, 1996, now abandoned. (76) Inventor: David Lew Simon, Mansfield Center, CT (US) Publication Classification Correspondence Address: (51) Int. Cl. ................................................ A61K 31/485 David L. Simon (52) U.S. Cl. .............................................................. 514/282 P.O. Box 618 100 Cemetery Road (57) ABSTRACT Mansfield Center, CT 06250 (US) The invention is directed in part to dosage forms comprising a combination of an analgesically effective amount of an (21) Appl. No.: 10/628,089 opioid agonist analgesic and a neutral receptor binding agent or a partial mu-opioid agonist, the neutral receptor binding (22) Filed: Jul. 25, 2003 agent or partial mu-opioid agonist being included in a ratio Related U.S. Application Data to the opioid agonist analgesic to provide a combination product which is analgesically effective when the combina (63) Continuation-in-part of application No. 10/306,657, tion is administered as prescribed, but which is leSS analge filed on Nov. 27, 2002, which is a continuation-in-part Sically effective or less rewarding when administered in of application No. 09/922,873, filed on Aug. 6, 2001, excess of prescription. Preferably, the combination product now Pat. No. 6,569,866, which is a continuation-in affects an opioid dependent individual differently from an part of application No. 09/152,834, filed on Sep.
    [Show full text]
  • Opioid Prescription Drug Monitoring Surveillance Report 2015
    Opioid Prescription Drug Monitoring Surveillance Report 2015 Department of Health and Human Services Division of Public Health Opioid Prescription Drug Monitoring Surveillance Report Release date: November 28, 2016 Report prepared by: Megan Key, BS Jamie S. White, MPH Melody Law, MD, MPH Olivia Kasirye, MD, MS Sacramento County Department of Health and Human Services Public Health Division Disease Control and Epidemiology Unit 7001‐A East Parkway, Suite 600 Sacramento, CA 95823 Phone: 916‐875‐5881 TTY: 877‐835‐2929 Website: www.scph.com i Opioid Prescription Drug Monitoring Surveillance Report Introduction Contents INTRODUCTION ....................................................................................................................................................................... 1 The Opioid Epidemic ........................................................................................................................................................... 1 Controlled Substance Utilization Review and Evaluation System (CURES) ........................................................................ 1 Prescriber Guidelines .......................................................................................................................................................... 2 Purpose ............................................................................................................................................................................... 2 Acknowledgments ..............................................................................................................................................................
    [Show full text]
  • The Main Tea Eta a El Mattitauli Mali Malta
    THE MAIN TEA ETA USA 20180169172A1EL MATTITAULI MALI MALTA ( 19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2018 /0169172 A1 Kariman (43 ) Pub . Date : Jun . 21 , 2018 ( 54 ) COMPOUND AND METHOD FOR A61K 31/ 437 ( 2006 .01 ) REDUCING APPETITE , FATIGUE AND PAIN A61K 9 / 48 (2006 .01 ) (52 ) U . S . CI. (71 ) Applicant : Alexander Kariman , Rockville , MD CPC . .. .. .. .. A61K 36 / 74 (2013 .01 ) ; A61K 9 / 4825 (US ) (2013 . 01 ) ; A61K 31/ 437 ( 2013 . 01 ) ; A61K ( 72 ) Inventor: Alexander Kariman , Rockville , MD 31/ 4375 (2013 .01 ) (US ) ( 57 ) ABSTRACT The disclosed invention generally relates to pharmaceutical (21 ) Appl . No. : 15 /898 , 232 and nutraceutical compounds and methods for reducing appetite , muscle fatigue and spasticity , enhancing athletic ( 22 ) Filed : Feb . 16 , 2018 performance , and treating pain associated with cancer, trauma , medical procedure , and neurological diseases and Publication Classification disorders in subjects in need thereof. The disclosed inven ( 51 ) Int. Ci. tion further relates to Kratom compounds where said com A61K 36 / 74 ( 2006 .01 ) pound contains at least some pharmacologically inactive A61K 31/ 4375 ( 2006 .01 ) component. pronuPatent Applicationolan Publication manu saJun . decor21, 2018 deSheet les 1 of 5 US 2018 /0169172 A1 reta Mitragynine 7 -OM - nitragynine *** * *momoda W . 00 . Paynantheine Speciogynine **** * * * ! 1000 co Speclociliatine Corynartheidine Figure 1 Patent Application Publication Jun . 21, 2018 Sheet 2 of 5 US 2018 /0169172 A1
    [Show full text]
  • Federal Register/Vol. 84, No. 26/Thursday, February 7, 2019/Notices
    2570 Federal Register / Vol. 84, No. 26 / Thursday, February 7, 2019 / Notices National Fire Protection Association Register pursuant to Section 6(b) of the Morrissette Drive, Springfield, Virginia (‘‘NFPA’’) has filed written notifications Act on October 22, 2018 (83 FR 53297). 22152. simultaneously with the Attorney Suzanne Morris, SUPPLEMENTARY INFORMATION: General and the Federal Trade The Commission disclosing additions or Chief, Premerger and Division Statistics Unit, Attorney General has delegated his changes to its standards development Antitrust Division. authority under the Controlled activities. The notifications were filed [FR Doc. 2019–01489 Filed 2–6–19; 8:45 am] Substances Act to the Administrator of for the purpose of extending the Act’s BILLING CODE 4410–11–P the Drug Enforcement Administration provisions limiting the recovery of (DEA), 28 CFR 0.100(b). Authority to antitrust plaintiffs to actual damages exercise all necessary functions with under specified circumstances. DEPARTMENT OF JUSTICE respect to the promulgation and implementation of 21 CFR part 1301, Specifically, NFPA has provided an Drug Enforcement Administration updated and current list of its standards incident to the registration of development activities, related technical [Docket No. DEA–392] manufacturers, distributors, dispensers, committee and conformity assessment importers, and exporters of controlled activities. Information concerning NFPA Bulk Manufacturer of Controlled substances (other than final orders in regulations, technical committees,
    [Show full text]